Encephalopathy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

DelveInsight's, "Encephalopathy Pipeline Insight 2024" report provides comprehensive insights about 70+ Encephalopathy companies and 70+ pipeline drugs in the Encephalopathy pipeline landscape. It covers the Encephalopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Encephalopathy Pipeline Report

* DelveInsight's Encephalopathy pipeline report depicts a robust space with 70+ active players working to develop 70+ pipeline therapies for Encephalopathy treatment.
* The leading companies working in the Encephalopathy market include Xenon Pharmaceuticals, Rebiotix, Axcella Health, Neurocrine Biosciences, Takeda, Praxis Precision Medicines, Stoke Therapeutics, Longboard Pharmaceuticals, Knoop Biosciences, Q-State Biosciences Inc., Ocera Therapeutics, and others.
* Promising Encephalopathy Pipeline Therapies in the various stages of development include RLS-0071, TAK-935, VSL#3, Rifaximin SSD, AST-120, Ornithine Phenylacetate, Flortaucipir F18, ZX008 (Fenfluramine Hydrochloride), Standard Medical Therapy, Lactulose, HPN-100, and others.
* May 2024:- Patricia Bloom- A Randomized Controlled Trial of VE303 to Treat Hepatic Encephalopathy. This research is studying the use of a new drug to learn about its safety and efficacy as a treatment for hepatic encephalopathy. Eligible participants will be enrolled and given oral antibiotics followed by 14 days of the study drug (placebo vs.VE303). There will be visits as well as other procedures to collect blood and stool samples, and have tests of your cognition (thinking) for this research study. The hypothesis is that VE303 will safely and effectively improve cognitive function in patients with a history of overt hepatic encephalopathy.
* April 2024:- Stoke Therapeutics Inc.- An Open-Label Study to Investigate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Antisense Oligonucleotide STK-001 in Children and Adolescents With Dravet Syndrome. Stoke Therapeutics is evaluating the safety and tolerability of single and multiple ascending doses of STK-001 in patients with Dravet syndrome. Change in seizure frequency, overall clinical status, and quality of life will be measured as secondary endpoints in this open-label study.
* April 2024:- Encoded Therapeutics- ENDEAVOR is a Phase 1/2, 2-part, multicenter study to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged 6 to

Request a sample and discover the recent advances in Encephalopathy Treatment Drugs @ Encephalopathy Pipeline Report [https://www.delveinsight.com/sample-request/encephalopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Encephalopathy pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Encephalopathy drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Encephalopathy clinical trial landscape.

Encephalopathy Overview

Encephalopathy is a broad term used to describe abnormal brain function or brain structure. (Encephalo= brain + pathy= disorder). The abnormality may be transient, recurrent, or permanent. The loss of brain function may be reversible, static and stable, or progressive with increasing loss of brain activity over time.

Find out more about Encephalopathy Treatment Landscape @ Drugs for Encephalopathy Treatment [https://www.delveinsight.com/sample-request/encephalopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Encephalopathy Emerging Drugs Profile

* XEN496: Xenon Pharmaceuticals
* AXA 1665: Axcella Health
* RBX 7455: Rebiotix

Encephalopathy Pipeline Therapeutics Assessment

The Encephalopathy pipeline report proffers an integral view of the Encephalopathy emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Learn more about the emerging Encephalopathy Pipeline Therapies @ Encephalopathy Clinical Trials Assessment [https://www.delveinsight.com/sample-request/encephalopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Encephalopathy Pipeline Report

* Coverage- Global
* Encephalopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Encephalopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Encephalopathy Companies- Xenon Pharmaceuticals, Rebiotix, Axcella Health, Neurocrine Biosciences, Takeda, Praxis Precision Medicines, Stoke Therapeutics, Longboard Pharmaceuticals, Knoop Biosciences, Q-State Biosciences Inc., Ocera Therapeutics, and others.
* Encephalopathy Pipeline Therapies- RLS-0071, TAK-935, VSL#3, Rifaximin SSD, AST-120, Ornithine Phenylacetate, Flortaucipir F18, ZX008 (Fenfluramine Hydrochloride), Standard Medical Therapy, Lactulose, HPN-100, and others.

Dive deep into rich insights for new drugs for Encephalopathy Treatment, Visit @ Encephalopathy Market Drivers and Barriers, and Future Perspective [https://www.delveinsight.com/sample-request/encephalopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Encephalopathy: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Encephalopathy- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* XEN496: Xenon Pharmaceuticals
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* RBX 7455: Rebiotix
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name; Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Encephalopathy Key Companies
* Encephalopathy Key Products
* Encephalopathy - Unmet Needs
* Encephalopathy - Market Drivers and Barriers
* Encephalopathy - Future Perspectives and Conclusion
* Encephalopathy Analyst Views
* Encephalopathy Key Companies
* Appendix

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=encephalopathy-pipeline-fda-approvals-unmet-needs-preclinical-and-discovery-stage-product-and-companies-2024-updated]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.